Tags

Type your tag names separated by a space and hit enter

A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections.
Epidemiol Infect 2009; 137(10):1396-404EI

Abstract

Vitamin D has been shown to be an important immune system regulator. Vitamin D insufficiency during winter may cause increased susceptibility to upper respiratory tract infections (URIs). To determine whether vitamin D supplementation during the winter season prevents or decreases URI symptoms, 162 adults were randomized to receive 50 microg vitamin D3 (2000 IU) daily or matching placebo for 12 weeks. A bi-weekly questionnaire was used to record the incidence and severity of URI symptoms. There was no difference in the incidence of URIs between the vitamin D and placebo groups (48 URIs vs. 50 URIs, respectively, P=0.57). There was no difference in the duration or severity of URI symptoms between the vitamin D and placebo groups [5.4+/-4.8 days vs. 5.3+/-3.1 days, respectively, P=0.86 (95% CI for the difference in duration -1.8 to 2.1)]. The mean 25-hydroxyvitamin D level at baseline was similar in both groups (64.3+/-25.4 nmol/l in the vitamin D group; 63.0+/-25.8 nmol/l in the placebo group; n.s.). After 12 weeks, 25-hydroxyvitamin D levels increased significantly to 88.5+/-23.2 nmol/l in the vitamin D group, whereas there was no change in vitamin D levels in the placebo group. There was no benefit of vitamin D3 supplementation in decreasing the incidence or severity of symptomatic URIs during winter. Further studies are needed to determine the role of vitamin D in infection.

Authors+Show Affiliations

Bone Mineral Research Center, Winthrop University Hospital, Mineola, NY, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19296870

Citation

Li-Ng, M, et al. "A Randomized Controlled Trial of Vitamin D3 Supplementation for the Prevention of Symptomatic Upper Respiratory Tract Infections." Epidemiology and Infection, vol. 137, no. 10, 2009, pp. 1396-404.
Li-Ng M, Aloia JF, Pollack S, et al. A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol Infect. 2009;137(10):1396-404.
Li-Ng, M., Aloia, J. F., Pollack, S., Cunha, B. A., Mikhail, M., Yeh, J., & Berbari, N. (2009). A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiology and Infection, 137(10), pp. 1396-404. doi:10.1017/S0950268809002404.
Li-Ng M, et al. A Randomized Controlled Trial of Vitamin D3 Supplementation for the Prevention of Symptomatic Upper Respiratory Tract Infections. Epidemiol Infect. 2009;137(10):1396-404. PubMed PMID: 19296870.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. AU - Li-Ng,M, AU - Aloia,J F, AU - Pollack,S, AU - Cunha,B A, AU - Mikhail,M, AU - Yeh,J, AU - Berbari,N, Y1 - 2009/03/19/ PY - 2009/3/20/entrez PY - 2009/3/20/pubmed PY - 2009/9/22/medline SP - 1396 EP - 404 JF - Epidemiology and infection JO - Epidemiol. Infect. VL - 137 IS - 10 N2 - Vitamin D has been shown to be an important immune system regulator. Vitamin D insufficiency during winter may cause increased susceptibility to upper respiratory tract infections (URIs). To determine whether vitamin D supplementation during the winter season prevents or decreases URI symptoms, 162 adults were randomized to receive 50 microg vitamin D3 (2000 IU) daily or matching placebo for 12 weeks. A bi-weekly questionnaire was used to record the incidence and severity of URI symptoms. There was no difference in the incidence of URIs between the vitamin D and placebo groups (48 URIs vs. 50 URIs, respectively, P=0.57). There was no difference in the duration or severity of URI symptoms between the vitamin D and placebo groups [5.4+/-4.8 days vs. 5.3+/-3.1 days, respectively, P=0.86 (95% CI for the difference in duration -1.8 to 2.1)]. The mean 25-hydroxyvitamin D level at baseline was similar in both groups (64.3+/-25.4 nmol/l in the vitamin D group; 63.0+/-25.8 nmol/l in the placebo group; n.s.). After 12 weeks, 25-hydroxyvitamin D levels increased significantly to 88.5+/-23.2 nmol/l in the vitamin D group, whereas there was no change in vitamin D levels in the placebo group. There was no benefit of vitamin D3 supplementation in decreasing the incidence or severity of symptomatic URIs during winter. Further studies are needed to determine the role of vitamin D in infection. SN - 1469-4409 UR - https://www.unboundmedicine.com/medline/citation/19296870/A_randomized_controlled_trial_of_vitamin_D3_supplementation_for_the_prevention_of_symptomatic_upper_respiratory_tract_infections_ L2 - https://www.cambridge.org/core/product/identifier/S0950268809002404/type/journal_article DB - PRIME DP - Unbound Medicine ER -